Chungnam National University, Korea

Sun-hee Woo has been Professor of Physiology in the College of Pharmacy at Chungnam National University in South Korea since 2003. Her research interests are atrial local Ca2+ signaling and regulations of contraction and rhythm in cardiac muscle. Dr. Woo graduated from SungKyunKwan University College of Pharmacy, received her PhD degree at POSTECH in 1999, and did her postdoctoral research at Georgetown University Medical Center. She has been continuously investigating the regulatory mechanisms for cardiac excitation-contraction coupling and mechano-transduction.

Yonsei University Wonju College of Medicine, Korea

Seung-Kuy Cha (PhD) serves as Professor in the Departments of Physiology and Global Medical Science at Yonsei University Wonju College of Medicine, Korea. After obtaining his PhD from Yonsei University in 2005, he pursued postdoctoral training at UT Southwestern Medical Center in Dallas, Texas, USA. Since 2010, he has directed a laboratory at Yonsei University, focusing on the endocrine FGF-Klotho axis, organelle medicine, and Ca2+ signaling. In 2024, he began his role as director of the BK21 Four Project, supported by national grants.

Ewha Womans University, Korea

Youn-Hee Choi obtained MD degree from Ewha Womans University College of Medicine, followed by PhD degree from Yonsei University College of Medicine. After completing doctoral studies, she pursued postdoctoral fellowships at the University of Alabama at Birmingham. Since 2008, she has served as a Professor in the Department of Physiology at Ewha Womans University College of Medicine. Throughout her academic career, she has demonstrated a deep commitment to advancing our understanding of pathophysiological mechanisms and potential treatments in chronic inflammation, aging, and cancer.

Inje University, Korea

Jin Han, MD, PhD
College of Medicine, Inje University
His research focuses on the pathophysiology of heart failure, with a focus on the cardiovascular bioenergetics and mitochondrial function regulation, metabolic pathways and therapeutic targets in heart failure.

Inje University, Korea

Professor Hyoung Kyu Kim is a professor at the Cardiovascular and Metabolic Disease Center at Inje University. He specializes in research on the physiological pathogenesis of cardiometabolic diseases and therapeutic target discovery targeting mitochondrial energy metabolism. His core research skills include physiological studies of mitochondrial function and cardiac dysfunction and omics-based proteomics-function studies. Research on treatment strategies through he has published more than 110 papers in the field of mitochondrial and cardiovascular and metabolic diseases. He received the 2014 Korean Physiological Society Emerging Physiologist Award and the 2022 ‘Yudang’ Best Academic Physiologist Award.

Seoul National University, Korea

Dr. Sung Joon Kim graduated Seoul National University College of Medicine, conducted PhD research at the same university (1997), and research fellow at Freiburg University (Germany). His research interest includes cardiovascular physiology, especially pulmonary arterial hypertension with right heart disease, and the electrophysiology of novel ion channels in immune cells. He published more than 185 peer-reviewed papers including J Physiol, J Gen Physiol, J Biol Chem, J Immunol, Basic Res Cardiol, ATVB, Sci Adv etc.

Seoul National University, Korea

Yong-Seok Lee received his PhD in neuroscience from Seoul National University in Korea, followed by post-doctoral training at UCLA where he investigated mechanisms underlying learning deficits in neurodevelopmental disorders. His current research focuses on molecular, cellular, and circuit mechanisms of learning, memory, and social behaviors in mice.

Chungnam National University, Korea

Sang-Min Park, Ph.D. is an Assistant Professor at the College of Pharmacy, Chungnam National University (CNU). He obtained B.S., M.S., and Ph.D. degrees from Korea Advanced Institute of Science and Technology (KAIST). He worked at Korea Institute of Oriental Medicine (KIOM) as a Senior Researcher. He has started a research group, the Systems Physiology Lab, at CNU. His research interests lie in (1) Data-Driven Drug Discovery, (2) Single-cell Analysis for Cancer Drug Resistance, and (3) Drug Repositioning for Natural Products.

Chonnam National University
Department of Pharmacology, Medical School

Dr. Kook’s research interests primarily focus on the molecular and cellular mechanisms underlying cardiovascular diseases, with a particular emphasis on post-transcriptional modifications and the regulatory roles of non-coding RNAs. He has explored how various non-coding RNAs influence cell signaling pathways and cellular differentiation in cardiovascular and muscular tissues. His work has significant implications in understanding the epigenetic regulation of cardiovascular diseases through post-translational modifications of histone or non-histone proteins, offering potential therapeutic targets for preventing or reversing cardiac and vascular remodeling.

The Catholic University of Korea, Korea
Department of Pharmacology, College of Medicine

As an Associate Editor, I am interested in unraveling the molecular mechanisms of intractable brain diseases and the discovery of pharmacological treatments. This endeavor aims to identify novel therapeutic targets and develop effective interventions for conditions that currently lack adequate treatment options.
Area of responsibility: neuropharmacology

Chungnam National University, Korea
Department of Pharmacy, College of Pharmacy

Therapeutic target and drug development for vascular cell dysfunction
Therapeutic target and drug development for metabolic syndrome
Discovery for post-transcriptional modification (PTM) target regulator in vascular diseases

Keimyung University, Korea
Department of Pharmaceutics, College of Pharmacy

The Cancer Molecular Pharmacology Lab conducts research on integrated anti-cancer treatment strategies using multi-omics approaches to identify and overcome drug resistance in human cancers. Specifically, we focus on drug development research at the molecular level to clarify the mechanisms of action and metabolic targets involved in acquiring resistance to targeted anticancer drugs.

Seoul National University, Korea
Department of Biomedical Sciences at Seoul National University College of Medicine

Prof. Lee's research area excels at the cutting edge of biomedical research, specializing in therapeutics, immunology and biotechnology. His research group is at the forefront of developing innovative therapies, including monoclonal antibodies, bispecific antibodies, and advanced cellular therapies such as CAR-T. His research explores the immune response in depth to unlock new protective mechanisms and improve human health. His research group is using state-of-the-art platforms to advance antibody discovery and development, underscoring our commitment to pioneering new frontiers in medicine.

Yonsei University, Korea
College of Pharmacy

The main research topic is high throughput screening (HTS) for drug discovery. Cell-based phenotypic screening techniques are mainly used. Targets of interest include various GPCRs, NMDARs, and gap junctions. Genome engineering using CRISPR/Cas9 as a tool for assay development is also a research topic.

Kangwon National University, Korea

My main research interests lie in understanding the pathophysiological mechanisms of liver diseases and metabolic disorders, such as obesity, type 2 diabetes, metabolic-associated steatotic liver disease (MASLD), liver fibrosis, and liver cancer. Central to my work is the identification of novel pharmacological targets and drug candidates that could lead to new therapeutic approaches. In particular, my lab is dedicated to exploring intercellular communication within the liver via the secretome, which may provide new insights into disease progression and potential treatment strategies.

Hanyang University, Korea
Department of Pharmacy, College of Pharmacy

The research interests have encompassed the effects and action mechanisms of medicines that target oncogenes and signaling pathways through post-translational modification in cancer. Polo-like kinase 1 has been focused on as one of the targets for developing anticancer drugs in intractable cancer including metastatic and chemoresistant lung cancer